mGem: Progress on the development of conjugate vaccines for Cryptococcus neoformans infections
mBio · 08.04.2026 · 17 (4)
DOI: 10.1128/mbio.03538-25 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift mBio, erschienen am 08.04.2026. Verfasst von Piotr R Stempinski und 2 weiteren Autor:innen. Beteiligte Einrichtung: W. Harry Feinstone Department of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Cryptococcus neoformans, Cryptococcosis, Fungal Vaccines, Vaccines, Conjugate. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases, National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
Cryptococcus neoformans is an important fungal pathogen that causes cryptococcosis, a life-threatening disease predominantly affecting immunocompromised individuals. Current estimates suggest that cryptococcosis is responsible for over 150,000 deaths annually, highlighting the need for the development of effective preventive measures. Early research utilizing polysaccharide filtrates (CneF) laid the groundwork for polysaccharide-containing vaccines, demonstrating partial protection in murine infection models. Further vaccine constructs made with purified extracellular polysaccharides (EPS) conjugated to protein carriers elicited strong antibody responses and enhanced survival. Recently, more attention was given to the purified capsule components glucuronoxylomannan (GXM) and glucuronoxylomannogalactan (GXMGal), with studies indicating that GXM conjugates can elicit protective effects. The development of semisynthetic polysaccharide-based vaccines offers a new approach to addressing lot-to-lot variability, enhancing consistency. In conclusion, strategies that advance from early crude formulations to more sophisticated conjugate and synthetic vaccines hold great promise for developing an effective vaccine to prevent and treat cryptococcal diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- W. Harry Feinstone Department of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
ORCID-Profile: Piotr R Stempinski, Samuel Rodrigues Dos Santos Junior, Arturo Casadevall
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
- National Heart, Lung, and Blood Institute
Zitieren
APA
Stempinski, P. R., Rodrigues Dos Santos Junior, S., & Casadevall, A. (2026). mGem: Progress on the development of conjugate vaccines for Cryptococcus neoformans infections. mBio, 17(4). https://doi.org/10.1128/mbio.03538-25
Vancouver
Stempinski PR, Rodrigues Dos Santos Junior S, Casadevall A. mGem: Progress on the development of conjugate vaccines for Cryptococcus neoformans infections. mBio. 2026;17(4). doi:10.1128/mbio.03538-25
BibTeX
@article{Stempinski2026,
author = {Stempinski, Piotr R and Rodrigues Dos Santos Junior, Samuel and Casadevall, Arturo},
title = {mGem: Progress on the development of conjugate vaccines for Cryptococcus neoformans infections},
journal = {mBio},
year = {2026},
volume = {17},
number = {4},
doi = {10.1128/mbio.03538-25}
}
EUVIMED